Severe atopic dermatitis in an Asian-Arabic population treated with dupilumab: A retrospective observational study

Dear Editor,
Atopic dermatitis (AD) is a common, inflammatory skin disease characterized by a TH2-deviated immune response in the acute phase and a TH2/TH1/TH17/TH22-skewed immune response in the chronic phase1 associated with pruritus. Dupilumab, a therapeutic targeting IL-4, IL-13 signalling pathways2, 3 and the first biologic approved for the treatment of moderate-to-severe AD4 demonstrated substantial efficacy, minor side effects and good tolerability.2 Long term real-world studies investigating the efficacy, safety and tolerability of dupilumab in AD patients have been conducted mainly in Caucasians, Hispanic and southeast Asian populations but not Asian-Arabic descent population. To fill this gap, we investigated dupilumab in AD patients among Asian-Arabic population of Qatari descent. In this retrospective observational study, 56 Qatari patients were included with comparable socioeconomic status and various variables were collected (Table 1).